A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
The primary objective of this study is:
• To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Inclusion Criteria:
Exclusion Criteria:
1. Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
Los Angeles, California 90033, United States
Torrance, California 90502, United States
Vienna, A-1090, Austria
Pleven, 5800, Bulgaria
Sofia, 1431, Bulgaria
Pessac, 33603, France
Milan, 20122, Italy
Sochi, 354057, Russia